The Trump administration just pushed a major regulatory pivot—cannabis is getting reclassified as a lower-risk controlled substance at the federal level. This isn't just drug policy noise; it signals a fundamental recalibration in how Washington views market sectors tied to plant-based therapeutics and alternative economies. The ripple effects could touch everything from investment flows to regulatory frameworks across different asset classes. When federal policy shifts this dramatically, markets tend to pay attention. Keep an eye on how this unfolds in coming weeks.